Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection.
Matthews GV, Bhagani S, Van der Valk M, Rockstroh J, Feld JJ, Rauch A, Thurnheer C, Bruneau J, Kim A, Hellard M, Shaw D, Gane E, Nelson M, Ingiliz P, Applegate TL, Grebely J, Marks P, Martinello M, Petoumenos K, Dore GJ, REACT study group, Protocol Steering Committee, Coordinating Centre, Site Principal Investigators
Controlling COVID-19 via test-trace-quarantine.
Kerr CC, Mistry D, Stuart RM, Rosenfeld K, Hart GR, Núñez RC, Cohen JA, Selvaraj P, Abeysuriya RG, Jastrzębski M, George L, Hagedorn B, Panovska-Griffiths J, Fagalde M, Duchin J, Famulare M, Klein DJ
COVID-19Reinfection Following Successful Direct-acting Antiviral Therapy for Hepatitis C Virus Infection Among People Who Inject Drugs.
Cunningham EB, Hajarizadeh B, Amin J, Hellard M, Bruneau J, Feld JJ, Cooper C, Powis J, Litwin AH, Marks P, Dalgard O, Conway B, Moriggia A, Stedman C, Read P, Bruggmann P, Lacombe K, Dunlop A, Applegate TL, Matthews GV, Fraser C, Dore GJ, Grebely J